The efficacy and safety of Chinese herbal medicine Guizhi Fuling capsule combined with low dose mifepristone in the treatment of uterine fibroids: a systematic review and meta-analysis of 28 randomized controlled trials

Lei, Yiming; Yang, Lili; Yang, Honglian; Li, Min; Ou, Li; Bai, Yang; Dong, Taiwei; Gao, Feng; Wei, Peifeng

doi:10.1186/s12906-023-03842-y

BMC Complementary Medicine and Therapies

Table 2 The characteristics of the included studies

From: The efficacy and safety of Chinese herbal medicine Guizhi Fuling capsule combined with low dose mifepristone in the treatment of uterine fibroids: a systematic review and meta-analysis of 28 randomized controlled trials

Study	Sample(T/C)	Study design	Age (T/C, years)	Interventions		Duration	Follow-up	Outcomes	Funding
Study	Sample(T/C)	Study design	Age (T/C, years)	Treatment	Comparator	Duration	Follow-up	Outcomes	Funding
Cao (2016) [38]	40/40	RCT	37.1 ± 2.5/36.8 ± 2.3	GZFL (3.72 g/d, qid) + MFP (12.5 mg/d, qd)	MFP(12.5 mg/d, qd)	3 months	NR	CER, FSH, LH, E₂, P	NR
Chen et al. (2008) [39]	35/35	RCT	36.4 ± 4.2/38.3 ± 5.1	GZFL (3.72 g/d, qid) + MFP (12.5 mg/d, qd)	MFP(12.5 mg/d, qd)	3 months	6 months	CER, UFV, FSH, LH, E₂, P, ADR	NR
Deng and Li (2010) [40]	33/36	RCT	38.9 ± 8.1/39.5 ± 8.9	GZFL (2.79 g/d, tid) + MFP (12.5 mg/d, qd)	MFP(12.5 mg/d, qd)	3 months	6 months	CER, UFV, UV, FSH, LH, E₂, P, ADR	NR
Fei (2017) [41]	39/39	RCT	34.19 ± 5.65/35.69 ± 6.35	GZFL (3.72 g/d, qid) + MFP (12.5 mg/d, qd)	MFP(12.5 mg/d, qd)	3 months	NR	CER, UFV, UV, FSH, LH, E₂, P	NR
Gu and Hu (2011) [42]	67/67	RCT	34.2 ± 7.2/35.5 ± 6.6	GZFL (3.72 g/d, qid) + MFP (12.5 mg/d, qd)	MFP(12.5 mg/d, qd)	3 months	NR	CER, UFV, E₂, P	NR
Hu (2013) [43]	69/69	RCT	43 ± 9/43 ± 8	GZFL (2.79 g/d, tid) + MFP (12.5 mg/d, qd)	MFP(12.5 mg/d, qd)	3 months	NR	CER, FSH, LH, E₂, P	NR
Li and Gao (2015) [44]	135/135	RCT	37.2/37.4 (years)	GZFL (3.72 g/d, qid) + MFP (12.5 mg/d, qd)	MFP(12.5 mg/d, qd)	3 months	NR	CER, UFV, UV, FSH, LH, E₂, P, ADR	NR
Li (2017) [45]	50/50	RCT	37.2 ± 4.1/36.7 ± 3.9	GZFL (2.79 g/d, tid) + MFP (12.5 mg/d, qd)	MFP(12.5 mg/d, qd)	4 months	NR	CER, UFV, UV, FSH, LH, E₂, ADR	NR
Liang (2017) [46]	49/49	RCT	37.31 ± 5.19	GZFL (3.72 g/d, qid) + MFP (10 mg/d, qd)	MFP(10 mg/d, qd)	3 months	NR	CER, UFV, UV, FSH, LH, E₂, P	NR
Lin (2019) [47]	44/43	RCT	36.5 ± 5.0/36.0 ± 5.0	GZFL (2.79 g/d, tid) + MFP (12.5 mg/d, qd)	MFP(12.5 mg/d, qd)	3 months	NR	CER, UFV, FSH, LH, E₂, P	NR
Liu (2016) [48]	59/59	RCT	34.8 ± 4.2/35.5 ± 4.7	GZFL (2.79 g/d, tid) + MFP (12.5 mg/d, qd)	MFP(12.5 mg/d, qd)	6 months	NR	CER, UFV, UV, FSH, LH, E₂, ADR, MF	NR
Luo (2012) [49]	39/39	RCT	43.38 ± 4.69/43.33 ± 4.78	GZFL (3.72 g/d, qid) + MFP (10 mg/d, qd)	MFP (10 mg/d, qd)	3 months	NR	CER, FSH, LH, E₂, P	NR
OU and Lan (2015) [50]	35/35	RCT	36.21 ± 6.19/36.55 ± 6.35	GZFL (2.79 g/d, tid) + MFP (12.5 mg/d, qd)	MFP (12.5 mg/d, qd)	4 months	NR	CER, UFV, UV, FSH, LH, E₂, ADR	NR
Qin (2015) [54]	54/54	RCT	41.9 ± 6.2/43.1 ± 5.8	GZFL (3.72 g/d, qid) + MFP (10 mg/d, qd)	MFP (10 mg/d, qd)	3 months	NR	CER, FSH, LH, E₂, P	NR
Sha and Zhu (2016) [51]	40/40	RCT	45 ± 1.4/44 ± 1.5	GZFL (3.72 g/d, qid) + MFP (12.5 mg/d, qd)	MFP (12.5 mg/d, qd)	6 months	6 months	CER, UFV, FSH, LH, E₂, P	NR
Si et al. (2019) [52]	50/50	RCT	38.76 ± 3.80/38.99 ± 3.46	GZFL (2.79 g/d, tid) + MFP (12.5 mg/d, qd)	MFP (12.5 mg/d, qd)	3 months	NR	CER, UFV, UV, FSH, LH, E₂, P	Henan Province Traditional Chinese Medicine Scientific Research Special Project (2015ZY02108)
Su (2013) [53]	61/61	RCT	34.6 ± 6.8	GZFL (3.72 g/d, qid) + MFP (12.5 mg/d, qd)	MFP (12.5 mg/d, qd)	3 months	NR	CER, UFV, FSH, LH, E₂, P	NR
Wang and Zhang (2021) [55]	41/41	RCT	38.97 ± 2.88/38.95 ± 2.86	GZFL (2.79 g/d, tid) + MFP (12.5 mg/d, qd)	MFP (12.5 mg/d, qd)	3 months	NR	CER, UFV, FSH, LH, E₂, P, ADR, MF	NR
Wei (2019) [57]	50/50	RCT	40.32 ± 0.58/40.03 ± 0.13	GZFL (2.79 g/d, tid) + MFP (12.5 mg/d, qd)	MFP (12.5 mg/d, qd)	3 months	NR	CER, FSH, E₂	NR
Wei (2014) [58]	43/43	RCT	35.3 ± 4.2/33.8 ± 6.8	GZFL (2.79 g/d, tid) + MFP (12.5 mg/d, qd)	MFP (12.5 mg/d, qd)	3 months	NR	CER, FSH, LH, E₂, P	NR
Xu (2017) [59]	70/70	RCT	38.42 ± 3.85/38.76 ± 3.92	GZFL (3.72 g/d, qid) + MFP (12.5 mg/d, qd)	MFP (12.5 mg/d, qd)	3 months	NR	CER, FSH, LH, E₂	NR
Yang (2018) [60]	54/54	RCT	40.1 ± 2.3/40.3 ± 2.5	GZFL (2.79 g/d, tid) + MFP (10 mg/d, qd)	MFP (10 mg/d, qd)	3 months	NR	CER, UFV, FSH, LH, E₂, P, ADR	NR
Yuan et al. (2021) [61]	54/54	RCT	40.02 ± 2.94/39.22 ± 3.86	GZFL (2.79 g/d, tid) + MFP (10 mg/d, qd)	MFP (10 mg/d, qd)	3 months	NR	CER, UFV, FSH, LH, E₂, P	NR
Zhang and Yi (2014) [62]	36/36	RCT	39.6 ± 4.2	GZFL (3.72 g/d, qid) + MFP (10 mg/d, qd)	MFP (10 mg/d, qd)	3 months	NR	CER, UFV, UV, FSH, LH, E₂, P, ADR	NR
Zhang et al. (2019) [63]	42/42	RCT	39.53 ± 7.15/38.13 ± 6.15	GZFL (2.79 g/d, tid) + MFP (10 mg/d, qd)	MFP (10 mg/d, qd)	3 months	NR	CER, UFV, UV, E₂, P, ADR	NR
Zhong (2020) [64]	26/26	RCT	42.5 ± 12.5/43.5 ± 11.5	GZFL (2.79 g/d, tid) + MFP (12.5 mg/d, qd)	MFP (12.5 mg/d, qd)	3 months	NR	CER, UFV, FSH, LH, E₂, ADR, MF, HE4	NR
Zhou (2016) [65]	28/27	RCT	36.54 ± 3.27	GZFL (3.72 g/d, qid) + MFP (12.5 mg/d, qd)	MFP (12.5 mg/d, qd)	3 months	NR	CER, E₂, P	NR
Wang (2004) [56]	64/62	RCT	40–55/41–53	GZFL (2.79 g/d, tid) + MFP (12.5 mg/d, qd)	MFP (12.5 mg/d, qd)	6 months	6 months	CER, FSH, LH, E₂, P	NR

T Treatment group, C Control group, NR Not report, GZFL Guizhi fuling capsule, MFP Mifepristone, t.i.d three times a day, qd One a day, CER Clinical efficiency rate, ADR Adverse drug reactions, UFV Uterine fibroids volume, UV Uterine volume, E₂ Estradiol, P Progesterone, FSH Follicle stimulating hormone, LH Luteinizing hormone, MF Menstrual flow

Back to article page

ISSN: 2662-7671

Contact us

Submission enquiries: bmccomplementarymedicineandtherapies@biomedcentral.com
General enquiries: ORSupport@springernature.com